Sage Journals: Discover world-class research

Abstract

Background:

The melanoma differentiation-associated gene-7 (Mda-7)/interleukin-24 (IL-24) is a tumor killing cytokine, the bystander effect of which can be enhanced through tethering to tumor homing peptides (THPs).

Materials and Methods:

After fusing tLyP-1, RGR, and buforin as THPs to Mda-7/IL-24, enzyme-linked immunosorbent assay (ELISA) was used to determine the secretion potency of the recombinant proteins. The killing potency of plasmids expressing IL-24, IL-24.tLyP1, IL-24.RGR, and buf.IL-24 were assessed, using MTT, Annexin/PI staining assays, as well as measuring the expression level of GADD-153 and BCL2-associated X (BAX) on Huh-7 cells. Three-dimensional structural analysis and protein–receptor interaction were also evaluated by modeling.

Results:

The ELISA result showed that contrary to IL-24.RGR and buf.IL-24, IL-24.tLyP-1 retained the secretion potency, similar to the native form. The viability assessments showed that IL-24 and IL-24.tLyP-1 had the most growth suppressive effects in comparison with the control group (p < 0.0001). Furthermore, IL-24 and IL-24.tLyP-1 had the highest apoptotic activity and significant upregulatory effect on the GADD-153 and BAX genes (p < 0.0003). The modeling showed that peptide modifications left no detrimental effect on IL-24 attachment to the cognate receptor.

Conclusion:

IL-24 can tolerate tLyP-1 peptide modification by retaining its secretion potency. Tethering tLyP-1 to IL-24 can induce more apoptosis than its modified versions by RGR or buforin.

Get full access to this article

View all access options for this article.

References

Pestka

, Krause

, Sarkar

, et al. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol, 2004; 22:929.

Rasoolian

, Kheirollahi

, Hosseini

. MDA-7/interleukin 24 (IL-24) in tumor gene therapy: Application of tumor penetrating/homing peptides for improvement of the effects. Expert Opin Biol Ther, 2019; 19:211.

Persaud

, De Jesus

, Brannigan

, et al. Mechanism of action and applications of interleukin 24 in immunotherapy. Int J Mol Sci, 2016; 17:869.

Dent

, Yacoub

, Hamed

, et al. MDA-7/IL-24 as a cancer therapeutic: From bench to bedside. Anticancer Drugs, 2010; 21:725.

Wang

, Peng

, Yu

, et al. Melanoma differentiation associated gene-7 and interleukin-24 selectively induces growth arrest and apoptosis in hepatocellular carcinoma cell lines in vitro. Zhonghua Wai Ke Za Zhi, 2007; 45:1202.

Wang

, Xue

, Yi

, et al. Melanoma differentiation-associated gene-7, MDA-7/IL-24, selectively induces growth suppression, apoptosis in human hepatocellular carcinoma cell line HepG2 by replication-incompetent adenovirus vector. World J Gastroenterol, 2006; 12:1774.

, Yi

, Chen

, et al. Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma. Med Oncol, 2014; 31:261.

Wang

, Liang

. Interleukin-24 and its receptors. Immunology, 2005; 114:166.

, Emdad

, Sauane

, et al. Unique aspects of mda-7/IL-24 antitumor bystander activity: Establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene, 2005; 24:7552.

10.

Corti

, Curnis

, Rossoni

, et al. Peptide-mediated targeting of cytokines to tumor vasculature: The NGR-hTNF example. BioDrugs, 2013; 27:591.

11.

Sugahara

, Teesalu

, Karmali

, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 2010; 328:1031.

12.

Laakkonen

, Vuorinen

. Homing peptides as targeted delivery vehicles. Integr Biol (Camb), 2010; 2:326.

13.

Gautam

, Kapoor

, Chaudhary

, et al. Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics. Curr Med Chem, 2014; 21:2367.

14.

Johansson

, Hamzah

, Payne

, et al. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A, 2012; 109:7841.

15.

Hamzah

, Kotamraju

, Seo

, et al. Specific penetration and accumulation of a homing peptide within atherosclerotic plaques of apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A, 2011; 108:7154.

16.

Laakkonen

, Åkerman

, Biliran

, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A, 2004; 101:9381.

17.

, Wang

, et al. Use of labelled tLyP-1 as a novel ligand targeting the NRP receptor to image glioma. PLoS One, 2015; 10:e0137676.

18.

Jang

, Kim

, Lee

J-W

, et al. Enhancement of the cancer targeting specificity of buforin IIb by fusion with an anionic peptide via a matrix metalloproteinases-cleavable linker. Peptides, 2011; 32:895.

19.

Park

, Yi

, Matsuzaki

, et al. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: The proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A, 2000; 97:8245.

20.

Wang

, Qu

, Gong

, et al. Targeting and eradicating hepatic cancer cells with a cancer-specific vector carrying the buforin II cene. Cancer Biother Radiopharm, 2013; 28:623.

21.

Zhang

. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 2008; 9:40.

22.

Logsdon

, Deshpande

, Harris

, et al. Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines. Proc Natl Acad Sci U S A, 2012; 109:12704.

23.

Delano

WL.

The analysis has performed by OFFline system. Online document at www.pymol.org www.xxooe/com Accessed on 2002.

24.

Guex

, Peitsch

. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis, 1997; 18:2714.

25.

Menezes

, Bhatia

, Bhoopathi

, et al. MDA-7/IL-24: Multifunctional cancer killing cytokine. Adv Exp Med Biol, 2014; 818:127.

26.

Zhang

, Kang

, Shi

, et al. mda-7/IL-24 induces apoptosis in human HepG2 hepatoma cells by endoplasmic reticulum stress. Oncol Rep, 2008; 20:437.

27.

Caudell

, Mumm

, Poindexter

, et al. The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol, 2002; 168:6041.

28.

Chada

, Mhashilkar

, Ramesh

, et al. Bystander activity of Ad-mda7: Human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther, 2004; 10:1085.

29.

Enback

, Laakkonen

. Tumour-homing peptides: Tools for targeting, imaging and destruction. Biochem Soc Trans, 2007; 35:780.

30.

Ruoslahti

. Tumor penetrating peptides for improved drug delivery. Adv Drug Deliv Rev, 2017; 110:3.

31.

Xiao

, Li

, Yang

, et al. RGD-IL-24, a novel tumor-targeted fusion cytokine: Expression, purification and functional evaluation. Mol Biotechnol, 2009; 41:138.

32.

Hosseini

, Hosseini

, Hashempour

, et al. Effect of RGD coupled MDA-7/IL-24 on apoptosis induction in a hepatocellular carcinoma cell line. Mol Med Rep, 2017; 15:495.

33.

Jamhiri

, Zahri

, Mehrabani

, et al. Enhancing the apoptotic effect of IL-24/mda-7 on the human hepatic stellate cell through RGD peptide modification. Immunol Invest, 2018; 47:335.

34.

Khodadad

, Hosseini

, Shenavar

, et al. Construction of expressing vectors including melanoma differentiation-associated gene-7 (mda-7) fused with the RGD sequences for better tumor targeting. Iran J Basic Med Sci, 2015; 18:780.

35.

Bina

, Hosseini

, Shenavar

, et al. The effect of RGD/NGR peptide modification of melanoma differentiation-associated gene-7/interleukin-24 on its receptor attachment, an in silico analysis. Cancer Biother Radiopharm, 2017; 32:205.

36.

Bina

, Shenavar

, Khodadad

, et al. Impact of RGD peptide tethering to IL24/mda-7 (Melanoma Differentiation Associated Gene-7) on apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 2015; 16:6073.

37.

Lin

, Lin

, Wang

, et al. Techniques for physicochemical characterization of nanomaterials. Biotechnol Adv, 2014; 32:711.

38.

Roth

, Agemy

, Kotamraju

, et al. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene, 2012; 31:3754.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.42 MB

The Evaluation of tLyP-1-Bound Mda-7/IL-24 Killing Activity on a Liver Tumor Cell Line

Abstract

Background:

Materials and Methods:

Results:

Conclusion:

Get full access to this article

References

Supplementary Material